Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P. Blagden, Hani Gabra, Jeffrey C. Goh et al.|Clinical Cancer Research|2018Cited by 66
Measurement of Plasma-Derived Substance P: Biological, Methodological, and Statistical ConsiderationsDonald E. Campbell, Steven D. Douglas, Andrew A. Lackner et al.|Clinical and Vaccine Immunology|2006Cited by 32
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.Sarah P. Blagden, Tarek Meniawy, Hani Gabra et al.|Journal of Clinical Oncology|2016Cited by 4